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Open acceAbstract Background: Few studies speciﬁcally focus on fatigue of (long-term) colorectal can- 
cer (CRC) survivors or compare fatigue levels with a normative population. Association 
between surviving multiple primary cancers and fatigue is also explored.
Methods: Survivors diagnosed from 1998 to 2009 were identiﬁed from the Eindhoven Cancer 
Registry. In total, 3739 (79%) respondents and an age- and gender-matched normative popu- 
lation (n = 338) completed questionnaires on fatigue and psychological distress.
Results: More survivors reported feeling fatigued than the normative population (39% versus 
22%, p < 0.0001). Short-term survivors (<5 years post-diagnosis) had the highest mean fatigue 
scores compared with long-term survivors (P5 years post-diagnosis) or the normative popu- 
lation (21 ± 7 versus 20 ± 7 versus 18 ± 5, p < 0.0001, respectively). Having primary cancers 
prior to CRC was associated with more fatigue. Surgery + chemoradiation was independently 
associated with fatigue (odds ratio (OR): 1.63, 95% conﬁdence interval (CI): 1.17–2.29,
p = 0.004) as were anxiety (OR: 1.16, 95% CI: 1.12–1.19, p < 0.0001) and depressive symptoms 
(OR: 1.38, 95% CI: 1.33–1.43, p < 0.0001).
Conclusions: Fatigue is a signiﬁcant problem, especially for short-term CRC survivors. The 
association between chemoradiation and fatigue suggests that patients could beneﬁt from 12 
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1958 M.S.Y. Thong et al. / European Journal of Cancer 49 (2013) 1957–1966better information on treatment side-effects. When treating fatigue, clinical care should also 
focus on survivors’ psychological needs, especially survivors of multiple primary cancers.
 2013 Elsevier Ltd. All rights reserved.1. Intro duction 
Improv ed detection and treat ment hav e increa sed 
survival after colorectal cancer (CRC).1,2 In the Nethe r-
lands, the num ber of survivors is projected to increase 
from 58,000 in 2009 to 92,000 by 2020, of whi ch
>50% will be long-t erm survi vors (P5 yea rs post-d iag- 
nosis).3 With more patients survi ving longer, the long- 
term eﬀects of cancer and its treatment on patie nts’
well-b eing is of increa sing impor tance.
CRC survi vors often report feeling fatigued whi ch
could be con sequent to their diseas e and treat ment.4–6
Fatigue can persi st long after treatment terminat ion 7
and impac ts negatively on qua lity of life.8 Breast cancer 
patien ts treated with adjuvant therapy report persi sting 
fatigue up to 10 years post- treatment 9 and past che mo- 
therapy treatment has been associ ated with poor er cur- 
rent qua lity of life in long-t erm breast cancer 
survivo rs.10 We pos tulate that fatigue morbidity will
only increa se amon g CRC survi vors with the broaden- 
ing indica tions and increasing prescr iption for (neo-
)adjuvant treatment s.11,12 Fatigue has been posit ively 
correlated with psycho logical distress among long-term 
breast and testicul ar cancer survi vors.13,14 How ever,
few studi es loo k speciﬁcally into fatigu e and its corre- 
lates of (long-term) CRC survi vors or compare fatigue 
levels with a normat ive popul ation.15,16
This study explore d fatigue preval ence in a large pop- 
ulation-bas ed sampl e of CRC survi vors with up to 10
years after diagnosi s and compared fatigue level s with 
an age- and gen der-matched nor mative popul ation.
We also investiga ted associ ations of clinical and psycho -
logical facto rs with fatigu e. We prev iously found that 
multiple primary cancers survi vors have poor er health 
status and more psychologi cal distress than singl e pri- 
mary cancer survi vors, notab ly amo ng short-ter m survi -
vors.17 There fore, we were also intrigued if fatigue levels 
will be associ ated with survi ving previous prim ary can- 
cers and psycho logical dist ress as 1-in-5 CRC survivo rs
have history of a previous primary cancer.172. Method s
2.1. Setting and particip ants 
This study pool ed data from two patien t-reporte d
outcome (PRO) studi es conducted in January 2009 
and Decem ber 2010 on CRC survi vors regis tered in
the Eindho ven Cance r Registr y (ECR) (Fig. 1). Deta ils 
of studi es are reported elsewh ere.18 In both studi es,
exclus ion criteria included cognitive impai rment, death prior to start of study (according to the ECR, the Cen- 
tral Bureau for Genealo gy and hos pital records ) or
unveriﬁable address es. A Medical Ethics Com mittee 
approved both studies.
Multiple prim ary cancer diagnose s, accessed through 
ECR, wer e deﬁned as all prim ary cancer diagno ses prior
to CRC diagnosi s. Thi s study also included all skin can- 
cer diagn oses (except basal cell carci noma) as pos sible 
primary cancer diagn oses.
PRO data were colle cted via PROFI LES (Patient
Reported Outc omes Follow ing Initial treatmen t and 
Long term Evaluat ion of Sur vivorsh ip) regis try.19 PRO-
FILES is linked direct ly to clini cal data from the ECR,
which compiles data of all incide nt cancer cases in the 
souther n part of the Nethe rlands, an area with 10 hos pi- 
tals servi ng 2.3 milli on inhabitan ts.20
Normative populati on data were access ed from Cen- 
tERpane l, an online hous ehold pan el represen tative of
the Dutch popul ation. Deta ils of the annu al data collec- 
tion, started in 2009 by our study group, are describ ed
elsewhere .21 The most recent data wave in 2011 also 
included a fatigu e asses sment . Fro m the 2040 (82%)
respondent s P18 years, a rando m age- and gender- 
matched normative sampl e (n = 338) was selected for 
this study, reﬂecting the dist ribut ion of the clinical sam- 
ple. Soc iodemogr aphic data such as age, gend er, mari tal 
status and comorbi dity were collected.2.2. Data collecti on
The data colle ction method of PROF ILES has been
described .18,19 In summary, survi vors wer e informed of
the study via a lett er from their (ex-)attending specia list.
Patients were reassu red that non- participat ion had no
consequen ces on follow- up care or treatment . Non- 
respondent s were sent a remind er lett er and que stion- 
naire within 2 months .2.2.1. Fatigu e Assessm ent Scale (FAS)
Thi s 10-item Dutch vali dated questio nnaire assesses 
how patie nts usual ly feel abo ut their fatigue. It has good 
psychomet ric propert ies 22 and was previously used with 
cancer patie nts.23 Respons es ranged on a ﬁve-point scale 
(1: never to 5: always).
2.2.2. Hospi tal Anxiety and Depr ession Scale (HADS)
Dis tress was asses sed with the HAD S que stionn aire,
with seven item s each asses sing anxiety and dep res- 
sion.24 Casen ess for anxiety (HADS-A) or depress ion 
(HADS-D) was indica ted with two cut-oﬀ scores :
P824,25 or P1126 for each sub scale.
2009 Data collection 2010 Data collection
5399 survivors ≤85 years at time of 
study and registered with rectal 
cancer between 1998 and 2007 
and living in the region of the ECR1
2219 survivors randomly selected 
using weights on tumor site, 
incident year and sex  
1 hospital declined participation: 279 Specialists from 10 hospital 
locations received an invitation 
letter to participate in this study 
Double selections: 39 
Unverifiable address: 150 
Patient demented /terminally ill: 6 
Tumor not staged: 56 
Initial diagnosis outside ECR: 7 
Status of the remaining 1940 
survivors checked against ECR1
and hospital records 
A questionnaire was sent to the 
remaining 1682 survivors 
311 (18%) patients did not complete 
the questionnaire of whom 70 
actively refused or were too ill 
1371 (82%) survivors returned a 
completed questionnaire  
Respondents from the 2009 and 2010 data 
collections: 3991 
14 respondents in 2010 data collection 
also completed a 2009 questionnaire. 
Their 2010 responses were excluded.   
Patients with other primary cancer 
diagnosis after CRC: 238    
Total respondents included in study:  3739  
Survivors who had been previously 
selected for 2009 CRC study: 2219  
6197 survivors ≤85 years at time 
of study and registered in the 
ECR with colon or rectal cancer,  
diagnosed between January 2000 
and June 2009 were eligible  
(Ex)-attending specialists from 10 
hospitals were invited for study 
participation and to allow access 
to 3978 patients 
1 participating hospital excluded its rectal 
cancer patients due to other ongoing 
research: 169 
Double selections: 36 
Unverifiable address: 341 
Patient demented/terminally ill: 63 
Tumor not staged: 83  
Status of the remaining 3809 
survivors were checked against 
ECR and hospital records
622 (19%) patients either actively refused 
or did not return the questionnaire 
A questionnaire was sent to the 
remaining 3286 survivors 
Respondents who completed both an 
online and paper questionnaire: 44 
2664 (81%) survivors returned a 
completed questionnaire  
2620 (81%) completed 
questionnaires of which 1043 
(40%) were completed online
Fig. 1. Flowchar t of the patient selection. 1ECR: Eindho ven Cancer Registry.
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clinical data such as date of birth, date of diagnosi s,
tumour grade,27 clini cal stage,27 and primary treat ment.
Com orbidity at tim e of survey was asses sed with the 
adapted Self-admi nistered Comorb idity Quest ionnaire 
(SCQ).28 Soc ioeconomi c status was determined by an
indica tor developed by Statist ics Netherlands .29 Patient -
report ed demogra phic data included marital stat us, edu-
catio n, emp loymen t, lifest yle fact ors, wei ght and height .
PRO data from PROFI LES and the normat ive data
will be avail able for non-comm ercia l scientiﬁc resear ch,
subject to study que stion, privac y and conﬁdentiality 
restrict ions and regis tration (www.proﬁlesregist ry.nl ).2.3. Statisti cal analys es
We compared the patien t and tumour charact eristic s
of respondent s, non- responden ts and patie nts with 
unveriﬁable addresse s, using either t-tests or chi-square 
analys es. The non-p arametri c Kruska l–Wallis test was 
used, where approp riate.
The FAS mean scores of sho rt- and long-t erm survi -
vors and the nor mative popul ation wer e compared with
analys is of covari ance (ANCOVA). Conf oundin g vari- 
ables included for adjust ment were determ ined a pri- ori30: age at survey, gend er, marital status, education ,
comorbi dity at survey (yes/no), HAD S-A and HADS- 
D. ANCOVA analys es with only the survi vor groups 
adjust ed for age at survey, gender, marital status, edu ca- 
tion, socioeco nomic status, treatment , multiple primary 
cancers , comorbi dity at survey (yes/no), body mass 
index, HAD S-A and HADS -D.
We made two class iﬁcations of the total FAS score as
previous ly done 31: dichotom ous variab le, 10–21 (not
fatigued) and 22–50 (fatigued); and in tertil es, 10–21
(not fatigued ), 22–34 (fatigued) and 35–50 (very
fatigued).
Logist ic regression models using the dichotom ous 
FAS variab le were con ducted to identi fy predict ors of
fatigue. Predict ors wer e included stepwis e into the 
model: Model 1 consisting of demogra phic varia bles,
clinical varia bles added in Model 2 and psych ological 
distress variables in Mod el 3.
Due to multiple test ing, statistica l diﬀerences were 
indica ted at p < 0.01. Reported p-val ues wer e two-sided.
Clinic ally meani ngful diﬀerences were determined with 
Norm an’s ‘rule of thumb’, using 0.5 SD diﬀerence to
indica te a thres hold discr iminan t change in scores .32 All
statistica l analyses were perfor med using SAS (version 
9.2 for Wind ows, SAS Institut e Inc., Car y, NC, USA).
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From both data colle ction periods , 4968 elig ible survi -
vors recei ved study invitatio ns, of whom 933 did not 
respond and 490 had non-veri ﬁed address es. Comp arisons 
between respo ndents, non-res ponden ts and survivo rs
with non- veriﬁed address es are rep orted elsewhere .18 In
short, non-res ponden ts were signi ﬁcantly older, fema le,
were diagno sed with colon can cer, had stage II diseas e
and were more often treated with surger y only. Patients 
with non-veriﬁed address es had longer survi val time.
Excluded from the 2010 study wer e 14 responden ts
who also completed a questio nnaire in 2009, and 44
online questi onnaires as these responden ts also com- 
pleted a paper versi on. Ther e were no signiﬁcant diﬀer-
ences betwe en the 44 online and paper que stionnaire 
responses . Of the respo ndents, 238 diagnose d with other 
primary cancers after their CRC were excluded from 
further analyses as subsequ ent treat ment for the new
cancers could inﬂuence fatigu e levels. Final analyses 
included 3739 (79%) respon dents.
Compa risons on clinical characteris tics of respon- 
dents from the 2009 and 2010 studi es stratiﬁed by years 
since diagnosi s showe d that sho rt-term survivo rs were 
more likely to have colon cancer, to be treated with sur- 
gery + chemot herapy and had pre vious primary can cer,
while long-term survi vors were more likely to have stage 
I cancer (Table 1). Baseli ne varia bles that could be com- 
pared with the normat ive popul ation showe d diﬀerences
in education , employ ment, comorbi dity and anxiety and 
depress ive sympt oms. The normat ive popul ation was 
more likely to be highly educated and employ ed at time 
of survey. For comorbi dity, the normat ive populati on
was more likely to report back pain, with a trend for 
osteoar thritis but less likel y to have anxiety or dep res- 
sive sympt oms when compared with survivo rs. A trend 
signiﬁcance was also noted on the mean age of the whole 
sample, with long-t erm survivo rs being somew hat older 
compared with short-ter m survi vors and the nor mative 
populati on.
Survivor s wer e more likely to be classiﬁed as fatigued 
when compared with the normat ive popul ation (39%
versus 22%, p < 0.0001 ) (Table 2). In gen eral, sho rt-term 
survivo rs had the highest mean fatigu e sco re and the 
normat ive popul ation, the lowest. Adjus ted resul ts show
statistica lly and clinically signi ﬁcant diﬀerences for the 
items getting tired very qui ckly and pro blems with 
thinkin g clear ly betw een the normat ive populati on and 
the sho rt- but not long-term survivors.
Compa rison between the survi vor groups showe d sta- 
tistically signiﬁcant but not clinicall y meanin gful diﬀer-
ences on two FAS items, with short-ter m survivors 
more likely to report getting tired very quickly and not 
doing much during the day.
Survivor s with previous prim ary cancers , especi ally 
among long-t erm survivo rs, wer e more likely to be clas- 
siﬁed as fatigued or very fati gued compared with survi -vors of only CRC (short-term: 43% versus 41%; long- 
term: 40% versus 34%, p = 0.002) (Fig. 2). The norma- 
tive populati on was signiﬁcantly less likely to be class i-
ﬁed as fatigued or very fatigu ed when compared with 
the survi vors (p < 0.0001 ).
Sur vivors had signi ﬁcantly higher mean HADS-A 
and HAD S-D scores than the normat ive populati on
(both p < 0.0001 ), although these diﬀerences wer e not 
clinically meani ngful (Tabl e 3). Survivor s were also 
more likely to meet the HAD S-A and the HADS-D 
cut-oﬀ score than the nor mative popul ation. When lim- 
ited onl y to the survi vor group , a signiﬁcantly greater 
percent age of short-term survi vors met the cut-oﬀ score 
of 8 for HADS-D (p = 0.0007 ) but not HADS -A than 
the long-t erm survivors. No diﬀerences between the 
two clinical groups were found when using the more 
conserva tive cut-oﬀ sco re.
Usi ng P8 points as cut-oﬀ, a signiﬁcantly great er
percent age of short-ter m survi vors with previous pri-
mary cancers met the HAD S-A (29% versus 20–22%,
p < 0.0001 ) and the HADS-D (27% versus 13–22%,
p = 0.0007 ) cut-oﬀ sco res than short- term survi vors 
without multiple cancer diagno ses and long-term sur- 
vivors with/w ithout multiple cancer diagnose s. When
the cut-oﬀ sco re was P11, no diﬀerences in psycho- 
logical distress wer e found in short- or lon g-term sur-
vivors, with or without multiple cancer diagnose s. On
the SCQ , sim ilar depress ion prev alence rates in the 
past 12 months wer e foun d for the three groups 
(short-term: 6% versus long-term : 6% versus norm:
4%, p = 0.1). Among survivors who report ed having 
had depression in the past 12 months , 57% short- term 
survivors, 65% long-term survivo rs and 75% norma- 
tive popul ation report ed recei ving treatment 
(p = 0.2). Regar ding the burden of depress ion, a
greater percent age of short- and long-t erm survi vors 
(57% and 54%, respect ively) than normat ive popula- 
tion (33%) felt that dep ression inter fered with their 
activities, althoug h this diﬀerence was not signi ﬁcant
(p = 0.2).3.1. Logistic regression 
Model 1 consis ting of only socio- demogra phic 
variables sho wed that higher education (odds ratio 
(OR): 0.61, 95% conﬁdence interval (CI): 0.50–
0.74, p < 0.0001 ), high socioecono mic status (OR:
0.77, 95% CI: 0.66–0.89, p = 0.0005 ) and partner ed
relationshi p (OR: 0.73, 95% CI: 0.62–0.86,
p = 0.0003 ) were associ ated with lower fatigue risk 
(Tabl e 4).
With the inclusion of clinical variables in Model 2,
educatio n and relationshi p status remai ned signiﬁ-
cantly associ ated with fatigue. The signi ﬁcance of
socioeconom ic stat us decrease d to a trend (p = 0.01)
while age at survey showe d a trend signiﬁcance 
Table 1
Clinical and demograph ic characteri stics of colorecta l cancer survivors stratiﬁed by time since diagnosis and the normative population.
n (%) <5 years 
(n = 2320)
P5 years 
(n = 1419)
Norm 
(n = 338)
p-value 
Colon cancer 1494 (64) 837 (59) n.a. 0.001 
Treatment n.a. <0.0001 
SU only 1091 (47) 746 (53)
SU + RT 494 (21) 319 (22)
SU + CT 535 (23) 245 (17)
SU + RT + CT 165 (7) 105 (7)
CT only 24 (1) 1 (0.1)
RT only 2 (0.1) 1 (0.1)
Tumour stage n.a. <0.0001 
1 624 (27) 470 (33)
2 826 (36) 543 (38)
3 668 (29) 369 (26)
4 158 (7) 23 (2)
Unknow n 44 (2) 14 (1)
Tumour grade n.a. 0.04 
1 169 (7) 118 (8)
2 1432 (62) 881 (62)
3 269 (12) 193 (14)
4 3 (0.1) 1 (0.1)
Unknow n 447 (19) 226 (16)
Previous primary cancer diagnosis/ es (Yes) 310 (13) 139 (10) n.a. 0.001 
Comorbidit y at survey 0.2 
None 724 (31) 412 (29) 94 (28)
1 639 (27) 378 (27) 88 (26)
>1 957 (41) 629 (44) 156 (46)
Most common comorbid conditions at survey 
Heart disease 395 (17) 262 (18) 63 (19) 0.4 
Hyperten sion 729 (31) 472 (33) 114 (34) 0.4 
Diabet es 302 (13) 186 (13) 38 (11) 0.6 
Osteoar thritis 547 (24) 365 (26) 104 (31) 0.01 
Back pain 562 (24) 370 (26) 110 (32) 0.004 
Mean age at survey (±SD) 69 ± 10 70 ± 10 68 ± 11 0.01 
Median years since colorectal cancer diagnosis (interquartile range, IQR) 2.6 (2.1-3.4) 7.6 (6.3-9.1)
Male 780 (57) 580 (53) 188 (56) 0.09 
Married/co habitating 1753 (76) 1026 (72) 240 (71) 0.03 
Education a <0.0001 
Low 464 (20) 275 (20) 24 (7)
Medium 1352 (60) 839 (60) 180 (53)
High 443 (20) 274 (20) 134 (40)
Employme nt 0.001 
Workin g at time of survey 362 (16) 218 (16) 71 (21)
Socioecono mic status n.a. 0.33 
Low 481 (21) 271 (19)
Medium 917 (41) 569 (41)
High 800 (36) 535 (38)
Body mass index (BMI) n.a. 0.4 
<18.5 30 (1) 14 (1)
18.5–24.9 753 (33) 491 (36)
25.0–29.9 1077 (48) 645 (47)
P30 389 (17) 223 (16)
Currently smoke 259 (11) 147 (11) n.a. 0.3 
Currently consum e alcohol 1229 (63) 800 (66) n.a. 0.3 
Some variables exceed 100% due to rounding oﬀ; some variables do not add up to 100% due to missing data.
n.a.: these items were not assessed in the normative populatio n.
a Education: Low (no or primary school); Medium (lower general secondary education or vocational training); High (pre-university education,
high vocationa l training, university).
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Table 2
Mean fatigue scores (±SD) of colorectal cancer survivors by years since diagnosis and the normative population.
Fatigue Assessmen t Scale (FAS) items (range: 1–5) <5 years 
(n = 2320)
P5 years 
(n = 1419)
Norm 
(n = 338)
p-value 
Only 
survivors a
Norm + survivors b
I am bothered by fatigue 2.4 ± 1.0 2.3 ± 1.0 2.0 ± 0.8 0.3 <0.0001 
I get tired very quickly 2.4 ± 1.1 c 2.2 ± 1.0 1.8 ± 0.9 0.0005 <0.0001 
I do not do much during the day 2.3 ± 1.1 2.1 ± 1.0 1.9 ± 1.0 <0.0001 <0.0001 
I have enough energy for everyday life * 2.8 ± 1.4 2.7 ± 1.4 2.6 ± 1.4 0.9 0.9 
Physicall y, I feel exhausted 1.8 ± 1.0 1.7 ± 0.9 1.5 ± 0.7 0.6 0.003 
I have problems starting things 2.0 ± 1.0 1.8 ± 0.9 1.7 ± 0.8 0.1 0.01 
I have problems thinking clearly 1.7 ± 0.9 c 1.6 ± 0.8 1.3 ± 0.6 0.2 <0.0001 
I feel no desire to do anything 2.0 ± 0.9 1.9 ± 0.8 1.7 ± 0.8 0.02 0.003 
Mentally, I feel exhausted 1.6 ± 0.9 1.5 ± 0.8 1.3 ± 0.6 0.2 0.03 
When I am doing somethin g, I can concentrat e
quite well *
2.3 ± 1.4 2.3 ± 1.4 2.3 ± 1.3 0.8 0.4 
FAS mean total score 21 ± 7 20 ± 7 18 ± 5 0.1 <0.0001 
%Respo nders who meet the P22 cut-oﬀ score for fatigue 31
Fatigued 41 35 22 <0.0001 
a p-values adjusted for: age at survey, gender, marital status, education, socioecon omic status, treatment, multiple primary cancers, comorbidity ,
body mass index, HADS-A and HADS-D.
b p-values adjusted for: age at survey, gender, marital status, educatio n, comorbidity , HADS-A and HADS-D.
c Clinically meaningful diﬀerence32 detected betwee n indicated survivors and the normative population.
* Items are reverse scored.
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(OR: 0.99, CI: 0.98–1.00, p = 0.01). Among the clini- 
cal varia bles, short-ter m survi vorshi p (OR: 1.29, 95%
CI: 1.11–1.49, p = 0.001) and comorbi d conditions 
(OR: 1.95, 95% CI: 1.65–2.31, p < 0.0001) were signi f-
icantly associ ated with fati gue. Increas ing body mass 
index (BMI) (OR: 1.02, 95% CI: 1.00–1.04, p = 0.02)
and surger y + chemoradi ation (OR: 1.36, 95% CI:
1.03–1.81, p = 0.03) showe d a trend signiﬁcance for 
increa sed fatigue. Previous primary can cers wer e not 
associated with fatigue.
In Model 3, HADS -A (OR: 1.16, 95% CI: 1.12–
1.19, p < 0.0001 ) and HAD S-D (OR: 1.38, 95% CI:
1.33–1.43, p < 0.0001 ) sho wed strong associati on with 
fatigue. Following these psych ologic al facto rs’ inclu- 
sion, age at survey remained signiﬁcant while gender 
gained almos t to trend signi ﬁcance (OR: 0.80, 95%
CI: 0.66–0.96, p = 0.02), wher eby being male was 
associated with less fatigue. As for clinical varia bles,
comorbi dity (OR: 1.50, 95% CI: 1.22–1.84,
p < 0.0001 ) remai ned signi ﬁcant in this model albeit 
with strongly decreas ed OR as compared with Mod el
2. Improv ed signiﬁcance was noted for BMI (OR:
1.03, 95% CI: 1.01–1.05, p = 0.007), and sur- 
gery + chemoradi ation (OR: 1.63, 95% CI: 1.17–2.29,
p = 0.004) wher eby the OR for treatment increa sed 
from 1.36 in Model 2.
A sub analysis using only survi vors class iﬁed as either 
not fatig ued or very fatigued showe d a signiﬁcance for 
age (OR: 0.96, 95% CI: 0.93–0.98, p = 0.001), HADS -
A (OR: 1.21, 95% CI: 1.13–1.30, p < 0.0001) and 
HADS-D (OR: 1.80, 95% CI: 1.64–1.98, p < 0.0001 ) in
the full model.4. Discuss ion 
Thi s large populatio n-based study amon g CRC survi- 
vors showed that fatigu e remains a signi ﬁcant problem 
even up to 10 years pos t-diagnosi s. In gen eral, regardless 
of time since diagnosi s, CRC survivors report ed signiﬁ-
cantly higher levels of fatigue when compared with an
age- and gender- match ed normat ive popul ation. Clini- 
cally meani ngful diﬀerences were foun d for getting tired 
quickly and problem s with clear thinkin g. Short-term 
CRC survi vors, especially those with multiple cancer 
diagnose s, were more likely to report feeling very fati- 
gued compared with long-term survi vors. Pat ients who 
were younger, had comorbi d conditio ns, and higher 
HADS-A and HADS-D scores wer e more likely to
report feeling fatigued .
The survi vor grou p had higher levels of fatigue than 
the nor mative popul ation whi ch is consistent with other 
studies on long-t erm CRC survi vors compared with the 
control grou p.15,16 In our sampl e, 39% of survi vors were 
classiﬁed as fatigued or very fatigued. This is compara -
ble to a popul ation-b ased study of older survi vors of
colorectal, breast and prosta te cancers in which approx- 
imately 38% repo rted feel ing eithe r little or no energy in
a typic al week.33
Treatmen t with chemoradiati on was strong ly associ- 
ated with fatigu e which is in line with previous study 
on breast canc er survivo rs.9 Fur thermo re, survi vors 
were more likely to repo rt problem s thinki ng clearly 
than the nor mative popul ation. This ﬁnding sugge sts 
cognitive impai rments associ ated with chemot herapy 
or in combinat ion with other therapies, a phe nomeno n
commonl y known as ‘chem obr ain’. Cogni tive dysfunc- 
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Fig. 2. % Colore ctal cancer survivors stratiﬁed by years since last diagnosis (short-term: <5 years; long-term: P5 years) and multipl e primary 
cancer, and normative population by fatigue levels. Fatigue Assessment Scale (FAS) total score cut-oﬀs: not fatigued (10–21), fatigued (22–34) and 
very fatigued (35–50).22,31 Signiﬁcant diﬀerences were noted between the survivors and the normative population (p < 0.0001) and between short- 
and long-ter m survivors with/out multiple primary cancers (p = 0.002).
Table 3
Mean scores (±SD) and respondents (%) with anxiety and depressive symptoms .
Hospital Anxiety and Depression Scale (HADS) <5 years (n = 2320) P5 years (n = 1419) Norm (n = 338) p-value 
HADS-A 4.8 ± 3.8 4.5 ± 3.8 3.4 ± 3.2 <0.0001 a
HADS-D 4.9 ± 3.7 4.3 ± 3.6 3.8 ± 3.1 <0.0001 a
% above the P8 clinical cut-oﬀ24,25
HADS-A 22 20 10 <0.0001 
HADS-D 22 18 12 <0.0001 
% above the P11 clinical cut-oﬀ26
HADS-A 10 8 3 <0.0001 
HADS-D 9 7 3 0.0007 
a p-values for mean HADS- A and HADS-D scores were adjusted for: age at survey, gender, marital status, educatio n and comorbidity .
M.S.Y. Thong et al. / European Journal of Cancer 49 (2013) 1957–1966 1963tion consequen t to (neo)adjuvant therapy is well studied 
in breast cancer. Breast can cer patie nts treat ed with che- 
mother apy report ed problem s with both fatigue and 
cognit ive functi on up to 2 years post-d iagnosis.34 How -
ever a recent review repo rted that the associ ation 
betwe en treat ment and subject ive cogn itive dysfunct ion 
in breast can cer survivo rs was inconclus ive.35 Stud ies 
on the associ ations of chemot herapy, cognitive impai r-
ment and fatigu e among CRC survi vors are rare, and 
even more so among long-term survivors. A murine 
study on two commonl y used chemother apeutic agents 
for CRC, oxali platin and 5-ﬂuorouraci l, foun d an asso- 
ciation with impaired cognit ive functi on.36
Survivor s with history of previous cancers wer e more 
likely to be fatigued or very fatigued . Of inter est is the 
high percenta ge (40%) of long-term survi vors of multi- 
ple primary can cers who still feel fatigued yea rs afte r
their last cancer diagnosi s. This prevalenc e is compara- 
ble to short- term survivors with (43%) or withou t
(41%) prev ious cancer diagnose s. Could there be a bio- 
logic explanat ion? Cance r sympto ms such as fatigue have been associ ated with inﬂammation pro cesses 
started by the diseas e and its treatment .37 A longitu dinal 
study of gastr ointesti nal cancer patie nts unde rgoing che-
moradi ation found that overexpr ession of pro-inﬂam- 
mator y cytoki nes such as sTNF -R1 and IL-6 was 
associ ated with fatigue developm ent over course of
treatment .6 Sarcoidos is patie nts up to 10 years in remi s-
sion who were still fatigued have less prod uction of the 
anti-inﬂammator y Th2 cytok ine than their non- fatigued 
counterpar ts.38 Ther efore could mult iple prim ary cancer 
surviv ors exposed to repeated treatmen ts have residual 
low-gra de inﬂammation that cou ld increa se fatig ue? 
Anxiety and dep ressive sympt oms wer e strong ly asso- 
ciated with fatigue, con sistent with other studi es.13,14
The associ ation between psychologi cal distress and fati- 
gue could be confound ed by gender as the signiﬁcance of
this varia ble impro ved to almost trend signi ﬁcance afte r
psychologi cal distress varia bles were included in the 
regres sion model.
When the cut-oﬀ score of P8 was used, sho rt-term 
surviv ors with previous prim ary cance rs were most 
Table 4
Logistic model of factors associated with fatigue.
Model 1 (demographics) Model 2 (Model 1 + clinical) Model 3 (Model 2 + psychologic al)
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Block 1 (demographic variables)
Age at survey 0.99 0.99–1.00 0.06 0.99 0.98–1.00 0.01 0.98 0.97–0.99 <0.0001 
Male versus female 0.89 0.77–1.03 0.1 0.91 0.78–1.06 0.2 0.80 0.66–0.97 0.02 
High versus medium/lo w education 0.61 0.50–0.74 <0.0001 0.61 0.50–0.75 <0.0001 0.85 0.67–1.09 0.2 
High versus medium/lo w socioeconom ic status 0.77 0.66–0.89 0.0005 0.82 0.70–0.96 0.01 0.84 0.70–1.02 0.07 
Partner versus no partner 0.73 0.62–0.86 0.0003 0.72 0.60–0.86 0.0002 0.83 0.67–1.04 0.1 
Block 2 (clinical variable s)
Short- versus long-term survivors 1.29 1.11–1.49 0.001 1.12 0.94–1.35 0.2 
body mass index (BMI) 1.02 1.00–1.04 0.02 1.03 1.01–1.05 0.007 
Comorbid ity versus none 1.95 1.65–2.31 <0.0001 1.50 1.22–1.84 0.0001 
SU + RT versus SU 1.14 0.94–1.37 0.2 1.19 0.94–1.49 0.1 
SU + CT versus SU 1.15 0.95–1.39 0.1 1.22 0.96–1.54 0.1 
SU + RT + CT versus SU 1.36 1.02–1.81 0.03 1.63 1.17–2.29 0.004 
Multiple versus single primary cancer 1.09 0.88–1.36 0.4 1.07 0.81–1.41 0.6 
Block 3 (psychological variables)
HADS-A 1.16 1.12–1.19 <0.0001 
HADS-D 1.38 1.33–1.43 <0.0001 
OR: odds ratio; CI: conﬁdence interval.
Continuo us variables: time since diagnosis, age at survey, body mass index, HADS-A, HADS- D.
SU: surgery; RT: radiotherapy ; CT: chemother apy.
1964 M.S.Y. Thong et al. / European Journal of Cancer 49 (2013) 1957–1966likely to report anxiety or depress ive sympt oms. This is
underst andable given that diseas e progres sion and need 
for furt her treat ment could increa se psych ological dis- 
tress. From the SCQ, only 6% of the sho rt-term survi- 
vors report ed they had depression within the last 12
months while the HAD S resul ts indica te about 20% of
survivo rs woul d meet HAD S-A and HADS-D cut-oﬀ
scores of P8. Fur therm ore, only 57% of tho se short- 
term survi vors with dep ression on the SCQ report ed
being treated for their depression in comp arison to the 
75% rep orted by the normat ive popul ation. Howev er,
when the more conserva tive cut-oﬀ score of P11was
used, levels of psych ological dist ress wer e compara ble 
between sho rt- and long-term survi vors. Fur thermore,
preval ence of depress ion on the HAD S-D using the 
higher cut-oﬀ score was compara ble with that on the 
SCQ. Take n toget her, this suggest s that psycho logical 
distress , especi ally subcli nical levels (as identiﬁed with 
the low er HAD S cut-oﬀ score) could be unde r-recogn i-
sed and unde r-treat ed in this sampl e.
Our resul ts have clinical implicat ions. Broadening 
indica tion for (neo-)adjuvant treatment s in CRC indi- 
cate that patie nts need to be better infor med of (late)
side-eﬀects such as fatigue. Sur vivors of mult iple pri- 
mary cancers wer e more likel y to have problem s with 
fatigue years afte r last diagnosi s. Fur thermo re, these 
survivo rs (especially short- term) wer e more likely to
meet indica tors for psych ologica l distress whi ch were 
found to be strong ly associated with fatigu e. Therefor e
when treating fatigue, clinic al practice needs to increase 
attention to survivo rs’ psychologi cal needs especi ally 
survivo rs who have survived mult iple prim ary cancers 
as this is no longer a rare clinical pictur e.Stu dy lim itations include the unavail ability of fatigue 
informat ion from non- respondent s and survi vors with 
unveriﬁed add resses for compari son and its pos sible 
eﬀects on current resul ts remai n unknown. In addition,
the cross-sect ional study design limits the determinat ion 
of causal associ ation betwee n cancer- related facto rs and 
fatigue.
Never thele ss, the present study provides an impor -
tant contribu tion to the limit ed data on fatig ue of
(long-term) CRC survi vors. Strength s of this study 
include its populati on-based design with a high response 
rate from a large sampl e. Furtherm ore, we were able to
compare fatigue levels with an age- and gender- matc hed 
normative sampl e. Altho ugh psychologi cal distress was 
strongly associ ated with fatigue, there is evidence to sug- 
gest clinical facto rs such as treat ment or gett ing a new
cancer as contri buting factors. Further resear ch on
potential unde rlyin g biologi c mechan isms of fatigue 
among various canc er survi vors foll owed over a longer 
period of time is needed.
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